Introduction to coagulation and laboratory tests
|
|
|
- Cassandra Johns
- 5 years ago
- Views:
Transcription
1 Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven
2 Coagulation in a blood vessel: fibrin stabilises the hemostatic clot Platelet immunostaining Fibrin staining
3 Polymerisation of fibrin stabilises the hemostatic clot = secondary hemostasis
4 Expression of Tissue Factor (TF) and Factor VIIa on phospholipid surfaces in damaged tissues Norledge BV, et al. Proteins. 2003;53:640-8
5 VIIa/TF Initiation of coagulation
6 VIIa/TF Initiation of coagulation IX IXa X Xa
7 VIIa/TF Initiation of coagulation IX IXa X Xa Prothrombin Thrombin
8 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Prothrombin Thrombin Amplification
9 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Prothrombin Thrombin Amplification
10 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Prothrombin Thrombin Amplification
11 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Prothrombin Thrombin Amplification
12 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Sustained hemostasis Prothrombin Thrombin Amplification Fibrinogen Fibrin
13 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Sustained hemostasis Prothrombin Thrombin FXIII Amplification Fibrinogen Fibrin
14 FVIII is bound to vwf in plasma vwf FVIII A1
15 Activated Factor VIII as cofactor of Factor IXa Factor VIIIa Factor IXa A2 Factor X A1 A3 Factor Xa C2 Phospholipids Haemostasis X by Factor VIII
16 FV and FVIII binding to phospholipids Pratt et al., Nature 2000 Phospholipid binding site Basic residues Hydrophobic residues
17 FV and FVIII binding to phospholipids Pratt et al., Nature 2000 Phospholipid binding site Basic residues Hydrophobic residues
18 FV and FVIII binding to phospholipids Pratt et al., Nature 2000 Phospholipid binding site Basic residues Hydrophobic residues
19 FVII, FIX, FX, FII binding to phospholipids: Gla domain basic hydrophobic Phospholipids
20 FVII, FIX, FX, FII binding to phospholipids: Gla domain basic hydrophobic Val Leu Phe Gla Gla Phospholipids Ca ++ d Gla: carboxy glutamic acid
21 -carboxylase H COO - C Glutamic acid CH CH protein
22 -carboxylase - OOC COO - C -carboxy CH CH H glutamic acid COO - C Glutamic acid CH CH protein
23 vitamin K VKOR VKR vitamin K cycle oxidized vitamin K reduced vitamin K - OOC COO - C -carboxy CH -carboxylase H glutamic acid COO - C Glutamic acid CH CH protein CH
24 vitamin K VKOR anti-vit K VKR vitamin K cycle oxidized vitamin K reduced vitamin K - OOC COO - C -carboxy CH -carboxylase H glutamic acid COO - C Glutamic acid CH CH protein CH
25 Coagulation and phospholipids
26 Coagulation and phospholipids Modern times, 1936
27 Anti-phospholipid antibodies
28 Anti-phospholipid antibodies
29 Anti-phospholipid antibodies Thrombosis but no bleedings
30 Coagulation assays
31 XI XIa VIIa/TF Initiation of coagulation VIII IX VIIIa IXa V X Va Xa Sustained hemostasis Prothrombin Thrombin FXIII Amplification Fibrinogen Fibrin
32 Prothrombin time (PT) + TF + phospholipids + Ca ++
33 Prothrombin time (PT) VIIa + TF + phospholipids + Ca ++ X Xa Prothrombin Thrombin Fibrinogen Fibrin
34 Prothrombin time (PT) VIIa + TF + phospholipids + Ca ++ X Xa time between the addition of reagents to citrate plasma and detection of a clot. Prothrombin Thrombin Fibrinogen Fibrin
35 time (seconds) PT results
36 PT results time (seconds) percent (%) by comparison to PT with dilutions of plasma 13 sec = 100% 40 sec = 10%
37 PT results time (seconds) percent (%) by comparison to PT with dilutions of plasma 13 sec = 100% 40 sec = 10% Follow up of Anti-vit K treatment
38 PT results time (seconds) percent (%) by comparison to PT with dilutions of plasma 13 sec = 100% 40 sec = 10% International Normalized Ratio (INR) 13 sec = 1 40 sec = 3.5 Follow up of Anti-vit K treatment
39 APTT (Activated Partial Thromboplastin Time) + non physiological surface (glass, silica, kaolin) + phospholipids + Ca ++
40 APTT (Activated Partial Thromboplastin Time) Contact Activation pathway HK / PK XII XIIa + non physiological surface (glass, silica, kaolin) + phospholipids + Ca ++
41 APTT (Activated Partial Thromboplastin Time) Contact Activation pathway HK / PK XII XIIa + non physiological surface (glass, silica, kaolin) XI XIa IX IXa VIII VIIIa + phospholipids + Ca ++ V X Va Xa Prothrombin Thrombin Fibrinogen Fibrin
42 Interpretation of coagulations assays
43 Prolonged isolated PT PT VIIa X Xa Prothrombin Thrombin (IIa) Fibrinogen Fibrin
44 HMWK / PK Prolonged isolated PT XII XIIa APTT nl PT > XI XIa VIIa VIII IX VIIIa IXa V X Va Xa X Xa Prothrombin Thrombin (IIa) Prothrombin Thrombin (IIa) Fibrinogen Fibrin Fibrinogen Fibrin
45 Isolated prolonged PT (lower % value, increased INR) acquired decreased FVII early liver disease early anti-vit K treatment «anti-phospholipid» antibody * constitutive FVII defect * not bleeding disorders
46 HMWK / PK Prolonged isolated APTT XII XIIa APTT > PT nl XI XIa VIIa VIII IX VIIIa IXa V X Va Xa X Xa Prothrombin Thrombin (IIa) Prothrombin Thrombin (IIa) Fibrinogen Fibrin Fibrinogen Fibrin
47 Isolated prolonged APTT acquired inhibitor antibody (FVIII) «anti-phospholipid» antibody * constitutive Von Willebrand disease hemophilia A and B (FVIII, FIX) FXI FXII (contact activation pathway) vwf FVIII * * not bleeding disorders
48 Differential diagnosis of isolated prolonged APTT mix of patient s plasma with normal plasma
49 Differential diagnosis of isolated prolonged APTT mix of patient s plasma with normal plasma Correction of the APTT: DECREASED FACTOR low titer or slow acting antibody Factors XII, FXI, FIX, FVIII?
50 Differential diagnosis of isolated prolonged APTT mix of patient s plasma with normal plasma Correction of the APTT: NO correction of the APTT: DECREASED FACTOR low titer or slow acting antibody ANTIBODY Factors? inhibitor antibody? anti-phospholipid antibody?
51 Prolonged PT and APTT
52 HMWK / K APTT PT XII XIIa XI XIa VIIa VIII IX VIIIa IXa V X Va Xa X Xa Prothrombin Thrombin (IIa) Prothrombin Thrombin (IIa) Fibrinogen Fibrin Fibrinogen Fibrin
53 HMWK / K APTT PT XII XIIa XI XIa VIIa VIII IX VIIIa IXa V X Va Xa X Xa Prothrombin Thrombin (IIa) Prothrombin Thrombin (IIa) Fibrinogen Fibrin Fibrinogen Fibrin
54 Acquired prolonged aptt and PT Clinical state Deficiency advanced liver disease VII, V, IX, X, II vit K deficiency VII, IX, X, II acute DIC V massive blood transfusion V lupus inhibitor none after dilution antibody to FV V rare systemic diseases Gaucher s disease Nieman Pick disease Amyloid V, X heparin oral anticoag treatment VII, IX, X, II
55
Primary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )
Blood coagulation and fibrinolysis Blood clotting (HAP unit 5 th ) Vessel injury Antithrombogenic (Favors fluid blood) Thrombogenic (Favors clotting) 3 Major systems involved Vessel wall Endothelium ECM
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
Diagnosis of hypercoagulability is by. Molecular markers
Agenda limitations of clinical laboratories to evaluate hypercoagulability and the underlying cause for thrombosis what is the INR the lupus anticoagulant and the antiphospholipid antibody syndrome hassouna
Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University
In The Name God Coagulation an Overview Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Research hcenter Shiraz Medical University Bleeding Clotting Hemostasis Review of platelet function Platelets
Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.
Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin
Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
Important Considera/ons for Coagula/on Tests on Children and Neonates
Important Considera/ons for Coagula/on Tests on Children and Neonates Cindy Neunert, MD MSCS Associate Professor Pediatric Hematology/Oncology/Bone Marrow Transplant Columbia University Medical Center
Part IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
Prothrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
Sysmex Educational Enhancement and Development No
SEED Coagulation Sysmex Educational Enhancement and Development No 2 2016 An approach to the bleeding patient The purpose of this newsletter is to provide an overview of the approach to the bleeding patient
Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot
Hemostasis Clo)ng factors and Coagula4on Dr Badri Paudel www.badripaudel.com Hemostasis is defined as a property of circula4on whereby blood is maintained within a vessel and the ability of the system
PHASES OF HAEMOSTASIS
HAEMOSTASIS Maintains the integrity of a closed, highpressure circulatory system after vascular damage Vessel Wall Injury events in the vessel wall and in the blood which seal breach Delicate balance exists
UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
Chapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
ACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
Bleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon
Bleeding and Haemostasis Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon 1 Beeding Its escaping or extravasation of blood contents from blood vessels Types: - Arterial - Venous - Capillary Differences
Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
THROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
M B Garvey. University of Toronto
Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands
The LaboratoryMatters
Laboratory Medicine Newsletter for clinicians, pathologists & clinical laboratory technologists. A Initiative. HEMOSTASIS AND THE LABORATORY This issue highlights: Primary Hemostasis Screening Tests Case
WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION
WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT ARTICLES OUR STUDY BLEEDING CONTROL 5 POINT MODEL WO NDCLOT The WoundClot Principals for Effective Bleeding Control PRESENTATION Harnessing SCIENCE
Biochemical Reaction Networks and Blood Clotting
Biochemical Reaction Networks and Blood Clotting Yasmeen Hussain, Aaron Fogelson Abstract Following an injury to the walls of a blood vessel, platelet aggregation and blood coagulation are induced. Through
Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
Chapter 1. General introduction
Chapter 1 General introduction 8 Haemostasis All organs and tissues of higher organisms are provided with nutrients and oxygen through the bloodstream. The bloodstream is an extensive vascular system that
Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph
Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)
Emergency Blood and Massive Transfusion: The Surgeon s Perspective. Transfusion Medicine Update September 16 17, 2009
Transfusion Medicine Update September 16 17, 2009 Mandip S. Atwal, D.O. FACOS Carl M. Pesta, D.O. FACOS Agenda History Hemorrhagic shock Transfusion is Bad Transfusion Prevention Transfusion The Red Chest
Coagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
Easy bruising vs Coagulopathy
Easy bruising vs Coagulopathy Sept. 19, 2015 Lakehead Summer School Chris Hillis, MD MSc FRCPC hillis@hhsc.ca @HemeHillis Aim & Objectives Aim: To increase comfort in detecting non-pathologic bleeding
Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
Insights on the Quality of Coagulation Testing
Insights on the Quality of Coagulation Testing Piet Meijer ECAT Foundation The Netherlands No conflicts of interest HAEMOSTATIC BALANCE BLEEDING HAEMOSTATIC BALANCE THROMBOSIS HAEMOSTATIC BALANCE Thrombosis
Determination of APTT factor sensitivity the misguiding guideline
International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Determination
4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
Coagulation BEFORE Surgery
Coagulation BEFORE Surgery Lorenzo ALBERIO Médecin chef Hématologie générale et Hémostase Service et Laboratoire centrale d Hématologie CHUV, Lausanne Outline 1. Pre-op testing 2. Ongoing anticoagulation
Bleeding Disorders.1 MS4.24.Feb.19. Abdallah Awidi Abbadi.MD. FRCP.FRCPath Professor
Bleeding Disorders.1 MS4.24.Feb.19 Abdallah Awidi Abbadi.MD. FRCP.FRCPath Professor Email: abdalla.awidi@gmail.com Hemostasis BV Injury Neural Contact Damage/contact. Blood Vessel Constriction Reduced
General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013
General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding
Haemorrhagic Disorders. Dr. Bashar Department of Pathology Mosul Medical College
Haemorrhagic Disorders Dr. Bashar Department of Pathology Mosul Medical College Hemorrhagic Disorders These include Disorders of platelets. Disorders of blood vessels. Disorders of coagulation & fibrinolysis.
Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
Continuing Medical Education
Continuing Medical Education WHY DO HEMOPHILIACS BLEED? B.R. Agarwal Z.E. Currimbhoy Deficiency of coagulation factor VIII (antihemophilic factor) and coagulation factor IX (Christmas factor) result in
Topics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION
LABORATORY DIAGNOSIS OF PROTHROMBOTIC COAGULATION INHIBITORS Tissue Factor Pathway Inhibitor (TFPI) Lipoprotein Associated Coagulation Inhibitor (LACI) Extrinsic Pathway Inhibitor (EPI) Complexes with
True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
Hemostasis and. Blood Coagulation
Hemostasis and Blood Coagulation Events in Hemostasis The term hemostasis means prevention of blood loss. Whenever a vessel is severed or ruptured, hemostasis is achieved by several mechanisms: (1) vascular
Chapter 3. Haemostatic abnormalities in patients with liver disease
Chapter 3 Haemostatic abnormalities in patients with liver disease Ton Lisman, Frank W.G. Leebeek 1, and Philip G. de Groot Thrombosis and Haemostasis Laboratory, Department of Haematology, University
Bleeding Disorders HOPE Maram Al-anbar
Bleeding Disorders HOPE Maram Al-anbar 9-9 - 2014 ^^ Attention Please ^^ We ( correction team of pediatric package^hope/2010^ ) had decided to make one lecture of bleeding disorders in place of the two
Clinical Study Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism
International Endocrinology Volume 2012, Article ID 156854, 4 pages doi:10.1155/2012/156854 Clinical Study Procoagulant and Anticoagulant Factors in Childhood Hypothyroidism Nevin Kilic, 1 Yildiz Dallar,
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
Approach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
-Hashim ahmed is the one who wrote this sheet. I just edited it according to our record.
* Subjects of this lecture : - Hemostasis - Platelets, general information, their ultrastructure and role in hemostasis. - Definitions: Thrombus, Embolus, Arteriosclerosis and Atherosclerosis. *NOTE: Prof
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shima M, Hanabusa H, Taki M, et al. Factor VIII mimetic function
Balanced Transfusion Resuscitation
Transparency in Transfusion Medicine 2013 Balanced Transfusion Resuscitation HGD Hendriks MD, PhD University Medical Center Groningen Balancing 1 2 3 Preoperative Peroperative Postoperative Balanced Coagulation
Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
Approach to bleeding
Approach to bleeding By Assoc. Prof. Darintr Sosothikul, MD Pediatric Hematology-Oncology division, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University The mechanism of
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]
![Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]](/thumbs/90/103064695.jpg "Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]")
Hemodynamics Amir Kol DVM, Ph.D, Dip ACVP (Clinical Pathology) UC Davis, School of Veterinary Medicine akol@ucdavis.edu Objectives Understand the mechanisms that promote extravascular fluid accumulation
3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
BLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
Blood (II) Huawei Liang, PhD
Blood (II) Huawei Liang, PhD E-mail: hwliang@zju.edu.cn Physiological hemostasis 生理止血 The arrest of bleeding from a broken blood vessel -- that is, the stoppage of hemorrhage ( 出血 ) Three major events:
Review Article Sri Lanka Dental Journal 2016; 46(01) 05-13
Review Article Sri Lanka Dental Journal 2016; 46(01) 05-13 The Importance of Knowing the Patient s Clotting Profile before Dental Treatment N.A. Alles, N.S. Soysa Introduction Patients having bleeding
Welcome - objectives of rotation Bone marrow reading schedule Thursday seminar schedule Hematology Division calendar...
TABLE OF CONTENTS Page no. Welcome - objectives of rotation... 1 Bone marrow reading schedule... 2 Thursday seminar schedule... 3 Hematology Division calendar... 4 Fellow and residents responsibilities...
Overview 5/8/2017. Management Strategies for Bleeding and Thrombocytopenia in the Neonate
Management Strategies for Bleeding and Thrombocytopenia in the Neonate Kyle Annen, DO Medical Director Blood Bank, Transfusion Service and Hematology Mount Sinai Beth Israel Assistant Professor, Department
STIMULATION THROUGH TLR4 INCREASES FVIII INHIBITOR FORMATION IN A MOUSE MODEL OF HEMOPHILIA A
Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-213 STIMULATION THROUGH TLR4 INCREASES FVIII INHIBITOR FORMATION
Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
Clinical hemostasis. Bodó Imre
Clinical hemostasis Bodó Imre Phases of blood clotting I. Primary hemostasis (vascular + PLT) II. Secondery heamostasis (fibrin clot) III. Kontrol system (stopping the cascade) IV. Fibrinolysis Felületaktiválás
MANAGEMENT OF COMMON BLEEDING DISORDERS. Auro Viswabandya Department of Haematology, CMC, Vellore
MANAGEMENT OF COMMON BLEEDING DISORDERS Auro Viswabandya Department of Haematology, CMC, Vellore BLOOD CLOT : PRIMARY HAEMOSTASIS (Platelets) + SECONDARY HAEMOSTASIS (Coagulation Factors) HAEMOSTATIC DISORDERS
Haemostasis & Coagulation disorders Objectives:
Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?
HEMOSTATIC ADAPTATIONS FOLLOWING EXERCISE TRAINING IN PATIENTS WITH CANCER A THESIS SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL
HEMOSTATIC ADAPTATIONS FOLLOWING EXERCISE TRAINING IN PATIENTS WITH CANCER A THESIS SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE BY ASHLEY
Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations
Factor VIII Inhibitor Testing: Nijmegen Modifications, Experience and Recommendations Bert Verbruggen Radboud University Nijmegen Medical Centre The Netherlands 2-12-2008 DISCLOSURE None 2-12-2008 2 ECAT
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
fritsmafactor.com Coag QA: Why are we Different? Prothrombin Time 1980: PT Ratio Based on MRI PTR = PTpatient PTMRI
Coag QA: Why are we Different? 4-28-15 Objectives Coagulation Laboratory Quality Assurance Why Are We Different? Compute and report the PT/INR Computing the ISI Local INR validation Local ISI calibration
Bleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.
1 Bleeding disorders Objectives: 1. Discuss briefly the physiology of hemostasis. 2. Define the mechanisms of thrombocytopenia and the relative bleeding risk at any given platelet count. 3. Be able to
Immunizations, registries and antibioterrorism. Presented by: Lisa E. Hensley. Category A Agents
USAMRIID Immunizations, registries and antibioterrorism efforts Presented by: Lisa E. Hensley Category A Agents The U.S. public health system and primary healthcare providers must be prepared to address
Hemophilia: diagnostics and treatment
Hemophilia: diagnostics and treatment Eveline Mauser-Bunschoten Van Creveldkliniek department of benign hematology thrombosis and hemostasis What is hemophilia? Hemophilia A: deficiency of factor VIII
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
Notes compiled for Pediatrics. Blood & Lymph. (Med I, Block 6, BL)
Notes compiled for Pediatrics Blood & Lymph (Med I, Block 6, BL) Contents Class number Class Name Type Department Instructor BL 008 Globin Gene Disorders T7 BC/HE Dr. B Triggs-Raine BL 015 Pediatric Anaemia
Targeting a Network Anticoagulation Issue. Anthony J. Macchiavelli, M.D., FHM
Targeting a Network Anticoagulation Issue Anthony J. Macchiavelli, M.D., FHM Disclosure Statement Janssen - Speaker Bureau Nonbranded Janssen research MARINER Janssen research MERCURY PE Portola research
Hemostasis and Thrombosis 2nd Edition
v a d e m e c u m Hemostasis and Thrombosis 2nd Edition Thomas G. DeLoughery, M.D. Oregon Health Sciences University Portland, Oregon, U.S.A. L A N D E S B I O S C I E N C E GEORGETOWN, TEXAS U.S.A. VADEMECUM
Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD
Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic
Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
Case Report Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
Case Reports in Hematology, Article ID 484563, 4 pages http://dx.doi.org/10.1155/2014/484563 Case Report Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor Nicholas B. Abt, 1 Michael
Coagulopathy Case - 3. Andy Nguyen, M.D. 2009
Coagulopathy Case - 3 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 21 year-old male seen in the emergency room with a swollen, tender right knee. Patient is an electrician who had fallen to the ground an
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Clotting Factors and Antithrombin Effective Date... 4/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 8007 Table of Contents Coverage Policy...
FIGURE 1. Coagulation cascade. a = activated factor; Ca = calcium; PL = phospholipid. Adapted from Biochemistry, 2 with permission from American Chemi
CONCISE REVIEW FOR CLINICIANS PROLONGED PT AND APTT How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults ARIF H. KAMAL, MD; AYALEW
HEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision
Quality Time saving Economy Practicability Quality assurance Precision exclusive distributor of for France, Netherlands, Belgium and Luxembourg List of frozen reagents In 1992, Precision BioLogic began
Thrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
A Patient with a Prolonged Activated Partial Thromboplastin Time and a Deep Intracerebral Haemorrhage
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
Approach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
Routine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
The changing face of massive transfusion
The changing face of massive transfusion HAABB, Kansas City, 18 April 2018 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine Medical Director, Transfusion Service, Harborview MC U of
Anticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
Coagulation Pathway and Physiology
Chapter 1 Coagulation Pathway and Physiology Russell A. Higgins, M Introduction Our understanding of blood clotting is intimately tied to the history of civilization. With the advent of writing 5000 years
1990s DTI. 1980s LMWH
1930s Heparin Parenteral Narrow therapeutic index Unpredictable Monitoring HIT Bleeding risk 1950s Warfarin Narrow therapeutic index Unpredictable Drug interactions Monitoring Bleeding risk 1980s LMWH
Reprinted in the IVIS website with the permission of the ACVP and ASVCP
Proceedings of the Annual Meeting of the American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology - Tucson, Arizona 2006 - Reprinted in the IVIS website with the